TSHA · Taysha Gene Therapies, Inc.
$3.96
-1.12% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-8.6
Dividend yield
0.0%
Beta
1.17
Avg volume
4M
Employees
0K
Daily Change %
-1.12%
5 Days Change
0.51%
10 Days Change
12.82%
30 Days Change
-17.33%
60 Days Change
-36.13%
Month to Day Change
-16.46%
Year to Day Change
-28.00%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TSHA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-17
Latest call per bank · past 12 months
Goldman Sachs
Buy$13.00
+228.3% vs priceBank of America
Buy$10.00
+152.5% vs priceWells Fargo
Overweight$11.00
+177.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-17 | Wolfe Research | Initiates | Outperform | $0.00 |
| 2026-07-21 | Goldman Sachs | Maintains | Buy | $11.00 → $13.00 |
| 2026-07-02 | Citizens | Reiterates | Market Outperform | $11.00 |
| 2026-06-30 | Needham | Maintains | Buy | $12.00 |
| 2026-06-30 | Baird | Maintains | Outperform | $12.00 → $15.00 |
| 2026-06-23 | BMO Capital | Maintains | Outperform | $10.00 → $14.00 |
| 2026-06-23 | Bank of America | Maintains | Buy | $9.00 → $10.00 |
| 2026-06-23 | Citizens | Maintains | Market Outperform | $8.00 → $11.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 21.1% below the 50-day MA ($5.02).
- bearish: Price vs 200-day MA: Trading 26.0% below the 200-day MA ($5.35).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.04) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($3.51) and high ($6.98).
TSHA Price Chart
Loading chart for TSHA…
Fundamentals
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.